Oral Micronized Progesterone Medicare Part D Coverage

Why Medicare Part D Matters for Progesterone Users

Oral micronized progesterone is the standard progestogen prescribed alongside estrogen in postmenopausal hormone replacement therapy (HRT) to protect the endometrium from hyperplasia [1]. The Endocrine Society's 2015 clinical practice guideline recommends micronized progesterone over synthetic progestins for most postmenopausal women because of a more favorable cardiovascular and breast-safety profile [2].

For the roughly 67 million Americans enrolled in Medicare, Part D prescription drug coverage determines what progesterone costs at the pharmacy counter [3]. Generic micronized progesterone capsules have been available since 2004, and the FDA's Orange Book rates them as "AB"-equivalent to Prometrium, meaning they deliver the same clinical effect [4]. That generic availability is the single biggest factor keeping Part D costs low.

Because Medicare beneficiaries skew older, progesterone prescriptions within Part D tend to cluster in women aged 50 to 65 who enrolled early through disability or women 65-plus continuing long-term HRT. The 2022 Hormone Therapy Position Statement from The North American Menopause Society (NAMS) endorses continued therapy past age 65 when the benefit-risk ratio remains favorable and the patient is informed [5].

How Part D Formularies Classify Progesterone

Part D formularies sort drugs into tiers. Generic micronized progesterone lands on Tier 1 (preferred generic) in most plans, which carries the lowest cost-sharing. Prometrium brand typically sits on Tier 3 or Tier 4.

The Centers for Medicare & Medicaid Services (CMS) requires every Part D plan to cover at least two drugs per therapeutic class [6]. Progestogens are well-represented across formularies, and generic progesterone capsules appear on the model formulary published annually by CMS [7]. A search of the Medicare Plan Finder for 2026 confirms that the vast majority of stand-alone Part D plans and Medicare Advantage Prescription Drug (MAPD) plans list generic progesterone without prior authorization or step therapy requirements.

Plans may impose quantity limits. A common limit is 30 capsules per 30 days for the 200 mg strength (cyclic dosing, 12 days per cycle) or 30 capsules per 30 days for the 100 mg strength used in continuous combined regimens. If your prescribed regimen exceeds the quantity limit, your clinician can submit a coverage determination request citing medical necessity per CMS Chapter 6 guidance on Part D coverage determinations [8].

What You Will Pay in 2026

The Inflation Reduction Act restructured Part D cost-sharing beginning in 2025. The $2,000 annual out-of-pocket cap, which eliminates the previous catastrophic-phase 5% coinsurance, remains in effect for 2026 [9]. Here is how each coverage phase affects your progesterone cost.

Initial deductible phase. The 2026 standard Part D deductible is $590. During this phase you pay 100% of the negotiated price. For generic progesterone, that negotiated price is often $8 to $20 for a 30-day supply, so you move through the deductible quickly. Some plans waive the deductible for Tier 1 generics entirely [10].

Initial coverage phase. After meeting the deductible, you pay a copay (typically $0 to $15 for Tier 1 generics) or coinsurance (25%) until combined spending reaches the coverage gap threshold.

Coverage gap. Manufacturers provide a discount on brand drugs in the gap, but generic drugs already carry low cost-sharing. Your generic progesterone copay stays roughly the same through this phase.

Catastrophic phase and the $2,000 cap. Once your true out-of-pocket spending hits $2,000, you pay $0 for the remainder of the year [9]. For a beneficiary whose only medication is generic progesterone at $10/month, this cap will likely never trigger from progesterone alone. But for patients on multiple medications, the cap provides meaningful relief.

Brand Prometrium vs. Generic: A Cost Comparison

Brand-name Prometrium can retail for $200 to $300 per month without insurance [11]. Generic micronized progesterone capsules retail for approximately $25 to $45 cash price, with some discount programs bringing the cost below $15 [4].

Under Part D, the brand sits on Tier 3 or higher. Expect a copay of $35 to $50 or coinsurance of 25% to 40% on brand tiers. The generic, by contrast, sits at $0 to $15. That difference of $20 to $45 per fill adds up to $240 to $540 per year.

The FDA requires generic drugs to demonstrate bioequivalence within 80% to 125% confidence intervals for key pharmacokinetic parameters (AUC and Cmax) [12]. Multiple generic manufacturers (Teva, Mylan/Viatris, Sun Pharma) produce micronized progesterone capsules that meet this standard. A 2016 analysis in the journal Menopause found no clinically significant difference in serum progesterone levels between Prometrium and its generic equivalents in postmenopausal women [13].

If your clinician writes "Dispense as Written" for brand Prometrium, your Part D plan will cover it at the higher brand tier, but you will bear the difference in cost-sharing. Ask whether the brand is truly necessary before accepting that added expense.

How to Lower Your Progesterone Cost on Medicare

Several strategies can bring your out-of-pocket cost down further.

Choose a plan with $0 generic copay. During Annual Enrollment (October 15 to December 7), use the Medicare Plan Finder to compare plans by entering your specific medications. Many MAPD plans in 2026 offer $0 copays for Tier 1 generics.

Use a preferred pharmacy. Part D plans maintain preferred pharmacy networks with lower copays. Filling at a preferred retail or mail-order pharmacy could reduce your per-fill cost by $3 to $8 [10].

Apply for Extra Help (Low-Income Subsidy). Beneficiaries with limited income and resources may qualify for the Part D Low-Income Subsidy (LIS), which reduces premiums, deductibles, and copays. Under full LIS, generic copays drop to $0 in 2026. The Social Security Administration processes applications [14].

Consider the Medicare Savings Programs. State Medicaid programs can pay Part D premiums and cost-sharing for qualifying individuals. Contact your State Health Insurance Assistance Program (SHIP) for enrollment guidance [15].

Manufacturer and pharmacy discount cards. While manufacturer coupons for brand Prometrium exist, they generally cannot be used by Medicare beneficiaries due to federal anti-kickback regulations [16]. However, independent pharmacy discount programs (GoodRx, RxSaver, Cost Plus Drugs) can sometimes beat the Part D negotiated price for generic progesterone when paying cash. Compare both options at the counter.

Compounded Progesterone: A Part D Caveat

Some women use compounded progesterone, often in custom-dose capsules or topical creams prepared by compounding pharmacies. These formulations are not FDA-approved and are not covered by Medicare Part D [17].

The NAMS 2022 Position Statement specifically cautions against compounded bioidentical hormones, noting that "custom-compounded hormones pose additional risks" related to variable potency and lack of FDA oversight [5]. Compounded progesterone costs roughly $25 per month cash, similar to generic FDA-approved capsules, so the financial incentive to compound is minimal while the regulatory and quality-control trade-off is significant.

If your clinician recommends a dose or route not available commercially (e.g., 50 mg capsules, vaginal suppositories), compounding may be appropriate, but Part D will not pay. This cost comes entirely out of pocket.

Prior Authorization and Step Therapy Scenarios

Generic oral micronized progesterone rarely triggers prior authorization (PA) on Part D. PA is more common for brand Prometrium, where plans may require documented generic failure or intolerance before covering the brand at a lower cost-sharing tier.

If your plan does impose PA, your prescriber submits a coverage determination. CMS requires plans to respond within 72 hours for standard requests and 24 hours for expedited requests when delay could jeopardize health [8]. If denied, you have the right to appeal through a five-level process outlined in the Medicare Prescription Drug Benefit Manual, Chapter 18 [18].

One clinical scenario that sometimes generates PA is off-label use. While progesterone is FDA-approved for secondary amenorrhea and endometrial protection during estrogen therapy, some clinicians prescribe it for luteal phase support in perimenopausal women. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 141 supports progesterone use across the menopausal transition [19]. Citing this guideline in a PA request strengthens the case.

Choosing the Right Part D Plan for HRT

Women on combined HRT (estrogen plus progesterone) should evaluate Part D plans holistically, not drug by drug. Enter all your medications into the Medicare Plan Finder to see total annual estimated costs, including premiums.

Key variables to compare:

• Whether the plan waives the deductible for generics
• Tier placement of both your estrogen product and progesterone
• Preferred pharmacy network (does it include your pharmacy?)
• Mail-order options for 90-day supplies, which often carry lower per-unit copays
• Whether the plan covers any non-formulary alternatives you might need

Dr. JoAnn Manson, chief of preventive medicine at Brigham and Women's Hospital, has noted: "The choice of progestogen matters. Micronized progesterone has consistently shown a better safety signal for breast and cardiovascular outcomes compared to synthetic progestins" [20]. That clinical preference aligns well with the cost picture: micronized progesterone generics are among the least expensive progestogens on Part D formularies.

The Women's Health Initiative (WHI) used medroxyprogesterone acetate (MPA), not micronized progesterone, in its estrogen-plus-progestin arm, and the increased breast cancer risk observed in that trial has not been replicated with micronized progesterone in observational studies such as the French E3N cohort (N=80,377), which found no significant increase in breast cancer risk with micronized progesterone use over a mean 8.1-year follow-up (RR 1.00 to 95% CI 0.83 to 1.22) [21].

What If You Do Not Have Part D?

Some Medicare beneficiaries opt out of Part D, either by choice or because they have creditable coverage through an employer or union plan. Without Part D, generic progesterone's cash price of $25 to $45 is manageable for most, but it pays to compare options.

Mark Cuban Cost Plus Drugs lists generic micronized progesterone at approximately $5 to $8 for a 30-day supply plus a flat dispensing fee and shipping [22]. Pharmacy discount cards may show prices of $8 to $18 depending on the pharmacy. These prices are sometimes lower than Part D copays, making it rational to pay cash even if you do have Part D coverage.

For the brand, patients without insurance can check the Prometrium manufacturer's patient assistance program. AbbVie (which acquired the Prometrium product line) maintains an Abbvie patient assistance portal for eligible uninsured or underinsured patients [4].

Late enrollment penalties apply if you go without creditable drug coverage for 63 or more consecutive days. The penalty is 1% of the national base beneficiary premium ($36.78 in 2026) multiplied by the number of uncovered months, added permanently to your Part D premium [23].